rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; our ability to restructure and to service our debt obligations; and any other factors referenced in our other filings with the applicable Canadian securities regulatory authorities or the Securities and Exchange Commission ("SEC"). For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K, and our quarterly report for the three months ended June 30, 2009 filed with the SEC on Form 10-Q.
Given these uncertainties, assumptions and risk factors, investors are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.
(C)2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.
About Angiotech Pharmaceuticals
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ:
Page: 1 2 3 4 5 6 7 8 Related biology technology :1
|SOURCE Angiotech Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference2
. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products3
. Tutogen Medical, Inc. to Report Fourth Quarter and Fiscal Year 2007 Financial Results4
. Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results5
. Nonin Medical, Inc. Receives Frost & Sullivans 2007 Award for Product Differentiation Innovation6
. Tutogen Medical, Inc. Reports First Quarter Fiscal 2008 Financial Results7
. Arobella Medical, LLC Launches Qoustic Wound Therapy System(TM)8
. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.9
. Tryton Medical, Inc. Closes $14 Million Financing10
. China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc.11
. Cohera Medical, Inc. Announces Closing of Insider Round of Financing for Over $7.6 Million